4',9,9'-Trihydroxy-3'-methoxy-3,7'-epoxy-4,8'-oxyneolignanCAS# 144881-21-0 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 144881-21-0 | SDF | Download SDF |
PubChem ID | 11393842 | Appearance | Oil |
Formula | C19H22O6 | M.Wt | 346.4 |
Type of Compound | Phenylpropanoids | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 4-[(2S,3S)-2-(hydroxymethyl)-6-(3-hydroxypropyl)-2,3-dihydro-1,4-benzodioxin-3-yl]-2-methoxyphenol | ||
SMILES | COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)CCCO)CO)O | ||
Standard InChIKey | VSJGYMSTWHUFMX-OALUTQOASA-N | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
4',9,9'-Trihydroxy-3'-methoxy-3,7'-epoxy-4,8'-oxyneolignan Dilution Calculator
4',9,9'-Trihydroxy-3'-methoxy-3,7'-epoxy-4,8'-oxyneolignan Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.8868 mL | 14.4342 mL | 28.8684 mL | 57.7367 mL | 72.1709 mL |
5 mM | 0.5774 mL | 2.8868 mL | 5.7737 mL | 11.5473 mL | 14.4342 mL |
10 mM | 0.2887 mL | 1.4434 mL | 2.8868 mL | 5.7737 mL | 7.2171 mL |
50 mM | 0.0577 mL | 0.2887 mL | 0.5774 mL | 1.1547 mL | 1.4434 mL |
100 mM | 0.0289 mL | 0.1443 mL | 0.2887 mL | 0.5774 mL | 0.7217 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Junipediol B
Catalog No.:BCN6252
CAS No.:144881-19-6
- Resiquimod (R-848)
Catalog No.:BCC4073
CAS No.:144875-48-9
- Garjasmin
Catalog No.:BCN6251
CAS No.:144868-43-9
- Alpiniaterpene A
Catalog No.:BCN7085
CAS No.:1448667-05-7
- Deflazacort
Catalog No.:BCC8928
CAS No.:14484-47-0
- 5-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
Catalog No.:BCC8720
CAS No.:144809-28-9
- L-703,664 succinate
Catalog No.:BCC7437
CAS No.:144776-01-2
- Brachynoside heptaacetate
Catalog No.:BCN6249
CAS No.:144765-80-0
- Clopidogrel Related Compound B
Catalog No.:BCN2688
CAS No.:144750-52-7
- Cyclo(Ala-Phe)
Catalog No.:BCN2411
CAS No.:14474-78-3
- Cyclo(Phe-Val)
Catalog No.:BCN2419
CAS No.:14474-71-6
- 2-4-Hydroxy-3-methoxyphenyl-7-methoxy-5-benzofuranpropanol
Catalog No.:BCN1564
CAS No.:144735-57-9
- MRS 2693 trisodium salt
Catalog No.:BCC7386
CAS No.:1448858-83-0
- ML314
Catalog No.:BCC4154
CAS No.:1448895-09-7
- 1-Methyl-aminomethyl naphthalene
Catalog No.:BCC8471
CAS No.:14489-75-9
- 18alpha-Glycyrrhetinic acid
Catalog No.:BCC8328
CAS No.:1449-05-4
- 21-Episerratenediol
Catalog No.:BCN6253
CAS No.:1449-06-5
- 24-Methylenecycloartanone
Catalog No.:BCN7244
CAS No.:1449-08-7
- 24-Methylenecycloartan-3-ol
Catalog No.:BCN6254
CAS No.:1449-09-8
- Androst-5-en-3-ol-7,17-dione acetate
Catalog No.:BCC8822
CAS No.:1449-61-2
- Senexin B
Catalog No.:BCC3990
CAS No.:1449228-40-3
- K145 hydrochloride
Catalog No.:BCC4072
CAS No.:1449240-68-9
- Chlojaponilactone B
Catalog No.:BCN7400
CAS No.:1449382-91-5
- Boeravinone O
Catalog No.:BCN6693
CAS No.:1449384-21-7
Crystal structure of 2,2''-bis-(2,7-di-chloro-9-hy-droxy-9H-fluoren-9-yl)-1,1':4',1''-terphenyl tri-ethyl-amine trisolvate.[Pubmed:26870400]
Acta Crystallogr E Crystallogr Commun. 2015 Nov 4;71(Pt 12):1439-43.
In the title solvate, C44H26Cl4O2.3C6H15N, the asymmetric part of the unit cell comprises two halves of the diol mol-ecules, 2,2''-bis-(2,7-di-chloro-9-hy-droxy-9H-fluoren-9-yl)-1,1':4',1''-terphenyl, and three mol-ecules of tri-ethyl-amine, i. e. the diol mol-ecules are located on crystallographic symmetry centres. Two of the solvent mol-ecules are disordered over two positions [occupancy ratios of 0.567 (3):0.433 (3) and 0.503 (3):0.497 (3)]. In the diol mol-ecules, the outer rings of the 1,1':4',1''-terphenyl elements are twisted with reference to their central arene ring and the mean planes of the fluorenyl moieties are inclined with respect to the terphenyl ring to which they are connected, the latter making dihedral angles of 82.05 (8) and 82.28 (8) degrees . The presence of two 9-fluoren-9-ol units attached at positions 2 and 2'' of the terphenyl moiety induces a 'folded' geometry which is stabilized by intra-molecular C-Hcdots, three dots, centeredO hydrogen bonds and pi-pi stacking inter-actions, the latter formed between the fluorenyl units and the central ring of the terphenyl unit [centroid-centroid distances = 3.559 (1) and 3.562 (1) A]. The crystal is composed of 1:2 complex units, in which the solvent mol-ecules are associated with the diol mol-ecules via O-Hcdots, three dots, centeredN hydrogen bonds, while the remaining solvent mol-ecule is linked to the host by a C-Hcdots, three dots, centeredN hydrogen bond. The given pattern of inter-molecular inter-actions results in formation of chain structures extending along [010].
Twist, tilt, and orientational order at the nematic to twist-bend nematic phase transition of 1'',9''-bis(4-cyanobiphenyl-4'-yl) nonane: A dielectric, (2)H NMR, and calorimetric study.[Pubmed:26764709]
Phys Rev E Stat Nonlin Soft Matter Phys. 2015 Dec;92(6):062505.
The nature of the nematic-nematic phase transition in the liquid crystal dimer 1'',9''-bis(4-cyanobiphenyl-4'-yl) nonane (CB9CB) has been investigated using techniques of calorimetry, dynamic dielectric response measurements, and (2)H NMR spectroscopy. The experimental results for CB9CB show that, like the shorter homologue CB7CB, the studied material exhibits a normal nematic phase, which on cooling undergoes a transition to the twist-bend nematic phase (N(TB)), a uniaxial nematic phase, promoted by the average bent molecular shape, in which the director tilts and precesses describing a conical helix. Modulated differential scanning calorimetry has been used to analyze the nature of the N(TB)-N phase transition, which is found to be weakly first order, but close to tricritical. Additionally broadband dielectric spectroscopy and (2)H magnetic resonance studies have revealed information on the structural characteristics of the recently discovered twist-bend nematic phase. Analysis of the dynamic dielectric response in both nematic phases has provided an estimate of the conical angle of the heliconical structure for the N(TB) phase. Capacitance measurements of the electric-field realignment of the director in initially planar aligned cells have yielded values for the splay and bend elastic constants in the high temperature nematic phase. The bend elastic constant is small and decreases with decreasing temperature as the twist-bend phase is approached. This behavior is expected theoretically and has been observed in materials that form the twist-bend nematic phase. (2)H NMR measurements characterize the chiral helical twist identified in the twist-bend nematic phase and also allow the determination of the temperature dependence of the conical angle and the orientational order parameter with respect to the director.
Spectroscopic and electrochemical behavior of newly synthesized high fluorescent symmetric 4'-nitrophenyl-3,4,9,10-perylenebisdiimide-azo hybrid dyes.[Pubmed:26125985]
Spectrochim Acta A Mol Biomol Spectrosc. 2015 Dec 5;151:72-9.
The investigation has been made in the synthesis of azo hybrid rylene dyes. The hybridization of perylene bis-diimide with phenolic azo-dyes was carried out by the nucleophilic substitution (SNAr) reaction of tetrachloroperylene-3,4,9,10-bisdiimide 3 with phenolic azo-dyes 4a-g in basic medium. The hybrid dyes exhibited two absorption maxima lambdamax in the range 300-350, 426-438 nm in ethanol due to presence of azo linkage and highly conjugated framework of pi bonds. Fluorescence spectra of these dyes in water showed sharp emission peaks with small bandwidths in the range 490-495 nm, and fluorescence quantum yield was 0.71-0.83 in comparison with standard reference fluorescein. The structures of perylene-azo dyes were elucidated by FTIR and NMR spectroscopy. Luminescence was determined by LS-100 meter which was found to be excellent in limits 0.208-0.239 cd/m(2). Cyclic voltammetric studies were made by Electrochemical Analyzer CH1830C which showed the oxidation chemical potential of these hybrid dyes.
Diethyl-4,4'-dihydroxy-8,3'-neolign-7,7'-dien-9,9'-dionate exhibits antihypertensive activity in rats through increase in intracellular cGMP level and blockade of calcium channels.[Pubmed:28159537]
Eur J Pharmacol. 2017 Mar 15;799:84-93.
We report here the antihypertensive and vasorelaxant potential of some steroidal and non-steroidal compounds identified through a library of compounds. All the novel analogues showed vasorelaxant potential in isolated rat aorta. The most potent lead neolignan1 (Diethyl-4,4'-dihydroxy-8,3'-neolign-7,7'-dien-9,9'-dionate) produced concentration dependent relaxation with [pD2 5.16+/-0.05; n=16 and Emax 96.97%+/-1.12%; n=16]. The neolignan1 relaxation is independent of endothelium and is sensitive to ODQ (1H-[1, 2, 4] oxadiazolo [4, 3-a] quinoxalin-1-one; a blocker of soluble guanylyl cyclase (sGC) which synthesizes cGMP (cyclic guanosine monophosphate)). ELISA analysis of treated arterial tissues showed concentration-dependent increase in cGMP level in treated tissues compared to control (2.03 and 7.16 fold of control at 10 and 30microM of neolignan1, respectively) and a synergistic increase in cGMP level by 26.66 fold compared to control when used in combination with sildenafil (10microM; a known inducer of cGMP level by selectively blocking cGMP specific phosphodiesterase 5). Our present study reports for the first time that neolignans produce relaxation in isolated rat aorta through increase in intracellular cGMP level. The ODQ resistant relaxation of neolignan1 is mediated by blockade of voltage dependent L-type calcium channel (VDCC) as observed in the experiment with CaCl2. Neolignan1 upon intravenous administration via tail vein in Spontaneously Hypertensive Rats (SHR) produced significant decrease in systolic blood pressure (SBP), diastolic blood pressure (DBP) and mean arterial blood pressure (MAP). The present study concludes that neolignan1 exhibited antihypertensive potential in rats through rise in intracellular cGMP and blockade of VDCC.